| Literature DB >> 27174321 |
Wen-Bo Wang1, Fei She2, Li-Fang Xie3, Wen-Hua Yan3, Jin-Zhi Ouyang3, Bao-An Wang3, Hang-Yun Ma3, Li Zang3, Yi-Ming Mu3.
Abstract
BACKGROUND: Prolonged gonadal hormone deficiency in patients with idiopathic hypogonadotropic hypogonadism (IHH) may produce adverse effects on the endocrine homeostasis and metabolism. This study aimed to compare basal serum adrenocorticotropic hormone (ACTH) and cortisol levels between male IHH patients and healthy controls. Moreover, this study compared the basal hypothalamic-pituitary-adrenal (HPA) axis in patients with and without nonalcoholic fatty liver disease (NAFLD), and also evaluated the relationship between basal HPA axis and NAFLD in male IHH patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27174321 PMCID: PMC4878158 DOI: 10.4103/0366-6999.181967
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
The clinical and biochemical characteristics of the male IHH patients and matched healthy controls
| Characteristics | Male IHH patients ( | Healthy controls ( | Statistical values | |
|---|---|---|---|---|
| Age (years) | 21.4 ± 3.7 | 21.1 ± 3.4 | 0.65* | 0.487 |
| BMI (kg/m2) | 23.66 ± 5.49 | 21.72 ± 3.94 | 2.98* | 0.008 |
| SBP (mmHg) | 118.79 ± 11.83 | 116.77 ± 12.76 | 1.19* | 0.262 |
| DBP (mmHg) | 71.09 ± 8.86 | 74.21 ± 8.07 | −2.62* | 0.011 |
| T (nmol/L) | 0.95 (0.57–1.81) | 18.32 (14.90–22.17) | 20.00† | <0.001 |
| LH (mU/ml) | 0.21 (0.02–0.81) | 3.51 (2.89–4.44) | 759.00† | <0.001 |
| FSH (U/L) | 0.93 (0.47–1.60) | 3.98 (2.91–5.14) | 1077.50† | <0.001 |
| FBG (mmol/L) | 4.66 ± 0.45 | 4.37 ± 0.99 | 2.17* | 0.031 |
| TG (mmol/L) | 1.32 ± 0.72 | 0.69 ± 0.31 | 7.87* | <0.001 |
| TC (mmol/L) | 3.98 ± 0.69 | 3.66 ± 0.64 | 2.94* | 0.004 |
| HDL-C (mmol/L) | 1.17 ± 0.28 | 1.32 ± 0.33 | −2.65* | 0.003 |
| LDL-C (mmol/L) | 2.38 ± 0.65 | 2.03 ± 0.54 | 3.68* | 0.001 |
| ALT (U/L) | 25.89 ± 20.60 | 17.14 ± 6.00 | 4.21* | 0.003 |
| AST (U/L) | 20.35 ± 8.77 | 17.37 ± 3.11 | 2.20* | 0.022 |
| GGT (U/L) | 19.87 ± 8.93 | 17.98 ± 8.73 | 1.30* | 0.094 |
| Cr (U/L) | 61.85 ± 8.70 | 71.85 ± 8.65 | −7.04* | <0.001 |
| ACTH (pmol/L) | 8.25 ± 3.78 | 6.97 ± 2.81 | 3.04* | 0.017 |
| Cortisol (nmol/L) | 366.70 ± 142.48 | 452.82 ± 141.53 | −0.88* | <0.001 |
| With NAFLD | 22 (34.9)‡ | 6 (4.4) | – | <0.001 |
Data are shown as mean ± SD, median (interquartile range), or n (%).*t values; †U values. ‡Among 75 male IHH patients, 63 patients were undergoing abdominal ultrasonography. IHH: Idiopathic hypogonadotropic hypogonadism; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; T: Serum testosterone; LH: Serum luteinizing hormone; FSH: Serum follicle-stimulating hormone; FBG: Fasting blood glucose; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; Cr: Serum creatinine; ACTH: Adrenocorticotropic hormone; NAFLD: Nonalcoholic fatty liver disease; SD: Standard deviation.
The clinical and biochemical characteristics of the 75 male IHH patients with and without HRT
| Characteristics | Patients with HRT ( | Patients without HRT ( | |
|---|---|---|---|
| Age (years) | 21.7 ± 3.7 | 20.8 ± 3.8 | 0.355 |
| BMI (kg/m2) | 24.01 ± 5.15 | 22.76 ± 6.31 | 0.425 |
| SBP (mmHg) | 120.22 ± 12.49 | 115.10 ± 9.19 | 0.157 |
| DBP (mmHg) | 72.02 ± 8.63 | 68.71 ± 9.19 | 0.164 |
| T (nmol/L) | 1.00 (0.62–1.94) | 0.76 (0.35–1.24) | 0.078 |
| LH (mU/ml) | 0.27 (0.03–1.03) | 0.15 (0.01–0.77) | 0.560 |
| FSH (U/L) | 1.01 (0.49–1.89) | 0.89 (0.42–1.56) | 0.715 |
| FBG (mmol/L) | 4.66 ± 0.50 | 4.65 ± 0.30 | 0.931 |
| TG (mmol/L) | 1.34 ± 0.75 | 1.26 ± 0.67 | 0.718 |
| TC (mmol/L) | 4.07 ± 0.74 | 3.80 ± 0.56 | 0.139 |
| HDL-C (mmol/L) | 1.14 ± 0.28 | 1.21 ± 0.26 | 0.383 |
| LDL-C (mmol/L) | 2.47 ± 0.69 | 2.17 ± 0.54 | 0.097 |
| ALT (U/L) | 26.74 ± 23.20 | 22.28 ± 8.55 | 0.205 |
| AST (U/L) | 21.24 ± 10.17 | 18.35 ± 3.79 | 0.133 |
| GGT (U/L) | 20.33 ± 10.30 | 16.45 ± 4.17 | 0.094 |
| Cr (U/L) | 63.43 ± 9.25 | 58.33 ± 6.21 | 0.121 |
| ACTH (pmol/L) | 8.02 ± 3.85 | 8.84 ± 3.92 | 0.311 |
| Cortisol (nmol/L) | 358.24 ± 153.24 | 371.97 ± 126.18 | 0.439 |
| With NAFLD | 15 (27.8) | 5 (23.8) | 0.543 |
Data are shown as mean ± SD, median (interquartile range), or n (%). HRT: Hormone replacement therapy; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; T: Serum testosterone; LH: Serum luteinizing hormone; FSH: Serum follicle-stimulating hormone; FBG: Fasting blood glucose; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; Cr: Serum creatinine; ACTH: Adrenocorticotropic hormone; NAFLD: Nonalcoholic fatty liver disease; SD: Standard deviation.
The clinical and biochemical characteristics of the 63 IHH patients with and without NAFLD
| Characteristics | NAFLD group ( | Non-NAFLD group ( | ||
|---|---|---|---|---|
| Age (years) | 22.91 ± 4.73 | 20.66 ± 2.89 | −2.34 | 0.051 |
| BMI (kg/m2) | 28.73 ± 5.42 | 20.57 ± 3.58 | −7.18 | <0.001 |
| SBP (mmHg) | 123.41 ± 10.70 | 116.10 ± 10.74 | −2.58 | 0.012 |
| DBP (mmHg) | 74.50 ± 9.53 | 68.24 ± 7.42 | −2.88 | 0.005 |
| FBG (mmol/L) | 4.68 ± 0.53 | 4.62 ± 0.43 | −0.76 | 0.625 |
| TG (mmol/L) | 1.59 ± 0.68 | 1.06 ± 0.64 | −2.58 | 0.013 |
| TC (mmol/L) | 4.33 ± 0.74 | 3.76 ± 0.60 | −2.80 | 0.007 |
| HDL-C (mmol/L) | 1.07 ± 0.28 | 1.22 ± 0.20 | 2.20 | 0.033 |
| LDL-C (mmol/L) | 2.64 ± 0.62 | 2.16 ± 0.61 | −2.57 | 0.013 |
| ALT (U/L) | 29.15 ± 14.40 | 22.85 ± 23.59 | −1.00 | 0.031 |
| AST (U/L) | 21.33 ± 10.51 | 19.52 ± 8.22 | −2.23 | 0.069 |
| GGT (U/L) | 24.49 ± 11.41 | 16.08 ± 6.82 | −7.98 | <0.001 |
| Cr (U/L) | 62.01 ± 7.31 | 61.05 ± 8.59 | −0.39 | 0.696 |
| ACTH (pmol/L) | 9.91 ± 4.98 | 7.60 ± 2.96 | −2.21 | 0.026 |
| Cortisol (nmol/L) | 349.43 ± 166.08 | 376.06 ± 146.47 | 3.58 | 0.553 |
| DHEAS (µg/L)* | 2123.7 ± 925.8 | 1417.1 ± 498.4 | −2.40 | 0.020 |
Data are shown as mean ± SD. *Among 63 patients who underwent abdominal ultrasonography, 39 subjects had records for DHEAS levels (11 in NAFLD group and 28 in non-NAFLD group). IHH: Idiopathic hypogonadotropic hypogonadism; NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FBG: Fasting blood glucose; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; Cr: Serum creatinine; ACTH: Adrenocorticotropic hormone; DHEAS: Dehydroepiandrosterone sulfate; SD: Standard deviation.
Correlation between ACTH, cortisol and metabolism parameters in male IHH patients
| Parameters | NAFLD | BMI | TC | TG | HDL | LDL | ALT | GGT | ACTH |
|---|---|---|---|---|---|---|---|---|---|
| ACTH | 0.289* | 0.143 | 0.239 | 0.268* | −0.143 | 0.135 | −0.066 | 0.208 | – |
| Cortisol | −0.001 | −0.052 | 0.098 | −0.086 | −0.138 | 0.079 | −0.173 | −0.047 | 0.484* |
*P<0.05. NAFLD: Nonalcoholic fatty liver disease; TC: Total cholesterol; TG: Triglycerides; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transpeptidase; ACTH: Adrenocorticotropic.
Multiple linear regression analysis for ACTH levels
| Variables | 95% | ||
|---|---|---|---|
| Constant | 8.303 | 0.000 | 6.738–9.868 |
| BMI | –0.087 | 0.554 | −0.380–0.206 |
| NAFLD | 3.232 | 0.013 | 0.704–5.761 |
| TC | 0.114 | 0.915 | −2.028–2.257 |
| TG | 1.324 | 0.215 | −0.797–3.446 |
| FBG | 2.150 | 0.120 | −0.588–4.888 |
CI: Confidence interval; BMI: Body mass index; NAFLD: Nonalcoholic fatty liver disease; TC: Total cholesterol; TG: Triglycerides; FBG: Fasting blood glucose.